MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
March 22 2022 - 6:05AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Scientific Officer, Thomas
Hofmann, MD, PhD, will participate in the Cantor Virtual Rare
Orphan Disease Summit on Tuesday, March 29, 2022 at 8:00 am (PT).
If you have interest in participating in the Cantor Virtual Rare
Orphan Disease Summit, please reach out to your Cantor Fitzgerald
representative.
About MannKind CorporationMannKind
Corporation (Nasdaq: MNKD) focuses on the development and
commercialization of inhaled therapeutic products for patients with
endocrine and orphan lung diseases. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company’s first FDA-approved product and the only inhaled ultra
rapid-acting mealtime insulin in the United States, where it
is available by prescription from pharmacies nationwide. Afrezza is
also available by prescription in Brazil, where it is
commercialized by the Company’s partner, Biomm
SA. MannKind was established in 1991, and is located
in Danbury, Conn., and Westlake Village, Calif. The
Company also employs field sales and medical representatives across
the U.S. Please visit mannkindcorp.com to learn
more.
Company Contact:Rose Alinaya,
Investor Relations(818) 661-5000Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024